SCHEMBL2020173

SCHEMBL2020173

CS(=O)(=O)Nc1ccc(OCCCN2CCN(c3ccc(F)c(F)c3)CC2=O)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 4/20 0.49
GRIN2B Q13224 4/20 0.49
LTA4H P09960 1/20 0.44
KCNH2 Q12809 5/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
HTR1A P08908 3/20 0.40
HTR1D P28221 2/20 0.40
IKBKB O14920 1/20 0.40
ADRB1 P08588 3/20 0.39
ADRB2 P07550 2/20 0.39
ADRB3 P13945 2/20 0.39
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
HTR2A P28223 2/20 0.36
DRD3 P35462 2/20 0.36
DRD2 P14416 1/20 0.36
DRD1 P21728 1/20 0.36
DRD5 P21918 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2048682 0.84 KCNH2 (0.58) GRIN1GRIN2BKCNH2ADRB1ADRB2
SCHEMBL2048683 0.84 KCNH2 (0.58) GRIN1GRIN2BKCNH2ADRB1ADRB2
SCHEMBL2019056 0.82 GRIN1 (0.73) GRIN1GRIN2BLTA4HKCNH2NPC1
SCHEMBL2019793 0.77 MAOB (0.48) KCNH2HTR1AHTR2ADRD3DRD2
SCHEMBL2018858 0.75 GRIN1 (0.75) GRIN1GRIN2BKCNH2HTR1AHTR1D
SCHEMBL2020637 0.73 GRIN1 (0.72) GRIN1GRIN2BKCNH2LMNA
SCHEMBL2017563 0.72 KCNH2 (0.77) KCNH2ADRB1ADRB2ADRB3LMNA
SCHEMBL1422302 0.72 KCNH2 (0.77) KCNH2ADRB1ADRB2ADRB3LMNA
SCHEMBL1422407 0.72 KCNH2 (0.77) KCNH2ADRB1ADRB2ADRB3LMNA
SCHEMBL2022536 0.72 MAOB (0.49) KCNH2HTR1AHTR2ADRD3DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2170334-B1 NMDA RECEPTOR ANTAGONISTS FOR NEUROPROTECTION UNIV EMORY (US) 2021-03-17 EP disclosed
EP-2170334-B1 NMDA RECEPTOR ANTAGONISTS FOR NEUROPROTECTION UNIV EMORY (US) 2021-03-17 EP disclosed
US-9079852-B2 NMDA receptor antagonists for neuroprotection EMORY UNIVERSITY (US) 2015-07-14 US disclosed
US-9079852-B2 NMDA receptor antagonists for neuroprotection EMORY UNIVERSITY (US) 2015-07-14 US disclosed
US-20140031363-A1 NMDA Receptor Antagonists for Neuroprotection LIOTTA DENNIS C (US) 2014-01-30 US disclosed
US-20140031363-A1 NMDA Receptor Antagonists for Neuroprotection LIOTTA DENNIS C (US) 2014-01-30 US disclosed
US-8420680-B2 NMDA receptor antagonists for neuroprotection EMORY UNIVERSITY (US) 2013-04-16 US disclosed
US-8420680-B2 NMDA receptor antagonists for neuroprotection EMORY UNIVERSITY (US) 2013-04-16 US disclosed
US-8420680-B2 NMDA receptor antagonists for neuroprotection EMORY UNIVERSITY (US) 2013-04-16 US disclosed
US-20110160223-A1 NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders EMORY UNIVERSITY 2011-06-30 US disclosed
US-20090253710-A1 NMDA Receptor Antagonists for Neuroprotection EMORY UNIVERSITY 2009-10-08 US disclosed
US-20090253710-A1 NMDA Receptor Antagonists for Neuroprotection EMORY UNIVERSITY 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253710-A1 NMDA Receptor Antagonists for Neuroprotection GRIN1, GRIN2C, GRIK1 GRIN1 1/4885GRIN2B 7/4885LTA4H 1822/4885
US-20110160223-A1 NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders GRIN2A, GRIN2B, GRIN1 GRIN1 3/4885GRIN2B 2/4885LTA4H 1766/4885
US-20140031363-A1 NMDA Receptor Antagonists for Neuroprotection GRIN1, GRIN2C, GRIK1 GRIN1 1/4885GRIN2B 7/4885LTA4H 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.